$BMEA News

Biomea Fusion Partners With The University Of Leicester For Ongoing Platform Research Study Titled 'Investigating And Optimizing Physical Function With Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial'

Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism

Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate

Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026

Citizens Initiates Coverage On Biomea Fusion with Market Outperform Rating, Announces Price Target of $9

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes Transcript

Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 Diabetes - Slideshow

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion Reveals 52-Week Results From Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment; In Patients Diagnosed Within 0-3 Years, Treatment With Icovamenib 200 Mg Once Daily For 12 Weeks Resulted In A 52% Increase In Mean C-peptide Area Under The Curve At Week 12

Biomea Fusion shares are trading higher after the company announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes.

Biomea Fusion shares are trading higher after the company announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes.

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion Starts New Trials to Test Diabetes Drug in Patients

Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript

Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts

Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes

Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript